CI Cigna Group Loading...

From COR earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
12:30
May 06 ◎
Bob Modge COR Q2 FY26 call
The speed of brand-to-biosimilar conversions at a large mail-order pharmacy customer was faster than anticipated, meaningfully reducing revenue growth but not operating income. — This suggests PBMs and mail-order pharmacies are insourcing biosimilar distribution faster than expected, which could pressure revenue for wholesale distributors but may not hurt their long-term profits.
CI
MED

About CI Analyst Coverage

Buzzberg tracks CI (Cigna Group) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Bob Modge.